Logo.jpg
LIXTE Receives U.S. Patent Issue Notification for Immune Oncology
September 04, 2024 08:30 ET | Lixte Biotechnology Holdings, Inc.
Patent Covers Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies PASADENA, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and...
Logo.jpg
First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company
August 26, 2024 08:30 ET | Lixte Biotechnology Holdings, Inc.
PASADENA, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”), today announced the dosing of the first patient in a new...
Logo.jpg
LIXTE Biotechnology Provides Update On Recent Activities and Developments
August 19, 2024 08:30 ET | Lixte Biotechnology Holdings, Inc.
-Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial by Major Pharma Company- -Distinguished Oncologist Jan Schellens Joins LIXTE as Chief Medical Officer- ...
Logo.jpg
LIXTE Biotechnology Holdings to Present at Two Investor Conferences
August 15, 2024 08:30 ET | Lixte Biotechnology Holdings, Inc.
-Company to Present August 20 at Investor Summit Summer 2024 Virtual Conference; and September 9-11 at H.C. Wainwright 26th Annual Global Investment Conference- PASADENA, CALIF., Aug. 15, 2024 ...
Logo.jpg
LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial
June 14, 2024 11:00 ET | Lixte Biotechnology Holdings, Inc.
Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE...
Logo.jpg
Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System
June 06, 2024 08:30 ET | Lixte Biotechnology Holdings, Inc.
LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System by Disrupting the Process of RNA Splicing PASADENA, CA, June 06, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology...
Picture1
LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer
June 03, 2024 08:30 ET | Lixte Biotechnology Holdings, Inc.
PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new...
Logo.jpg
LIXTE Biotechnology Holdings Provides Update on Recent Activities
May 20, 2024 08:30 ET | Lixte Biotechnology Holdings, Inc.
Publishing of Findings in Recent Pre-Clinical Study for LIXTE’s Proprietary Compound, LB-100, in New Field of Cancer Biology, “Activation Lethality”Presentation at MedInvest Biotech and Pharma...
Logo.jpg
LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”
May 08, 2024 09:25 ET | Lixte Biotechnology Holdings, Inc.
Recent Findings Relate to LIXTE’s Lead Clinical Compound, LB-100, to be Presented at Workshop on May 9 and 10 at Harvard’s Dana Farber Cancer Institute in Boston PASADENA, CA, May 08, 2024 (GLOBE...
Logo.jpg
NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES
March 27, 2024 08:30 ET | Lixte Biotechnology Holdings, Inc.
LB-100 IS SYNERGISTIC WITH WEE1 INHIBITION IN KILLING CANCER CELLS; FINDING OPENS NEW TREATMENT STRATEGY IN ADDITION TO THREE CURRENT LIXTE CLINICAL TRIALS PASADENA, CA, March 27, 2024 (GLOBE...